Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1500-pRCC,Adv, Sunitinib vs MET inhib | 1 | Y | 1 Sunitinib | 180 | 30 | 14 | 9 | 4 | 1 | 0 | 07/25/2016 | 213 | 88 |
| 2 Cabozantinib | 28 | 14 | 6 | 2 | 0 | 0 | ||||||||
| 3 Crizotinib | 28 | 12 | 7 | 0 | 0 | 0 | ||||||||
| 4 Savolitinib | 30 | 15 | 8 | 4 | 1 | 0 | ||||||||
| 116 | 55 | 30 | 10 | 2 | 0 | |||||||||
| S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 1 | Y | 1 TICE BCG | 969 | 66 | 47 | 30 | 12 | 5 | 0 | 02/24/2017 | 175 | 69 | |
| 2 Tokyo-172 BCG | 67 | 48 | 31 | 15 | 7 | 1 | ||||||||
| 3 Prime + Tokyo-172 BCG | 66 | 47 | 28 | 16 | 6 | 2 | ||||||||
| 199 | 142 | 89 | 43 | 18 | 3 | |||||||||
| S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab | 1 | Y | 1 Atezolizumab | 148 | 105 | 81 | 54 | 31 | 8 | 3 | 03/13/2017 | 192 | 88 | |
| 105 | 81 | 54 | 31 | 8 | 3 | |||||||||
| S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | 1 | Y | 0 Induction SST | 1273 | 22 | 22 | 22 | 22 | 6 | 0 | 09/24/2018 | 94 | 50 | |
| 22 | 22 | 22 | 22 | 6 | 0 | |||||||||
| 2 | Y | 1 Standard Systemic Therapy Only | 1273 | 4 | 4 | 4 | 4 | 1 | 1 | 09/24/2018 | ||||
| 2 SST + Surgery/RT | 4 | 4 | 4 | 4 | 1 | 0 | ||||||||
| 8 | 8 | 8 | 8 | 2 | 1 | |||||||||
| Yes | A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 1 | E | Total Registrations | 4 | 2 | 1 | 1 | 0 | 0 | 11/23/2016 | 57 | 34 | |
| 4 | 2 | 1 | 1 | 0 | 0 | |||||||||
| EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) | 0 | E | Total Registrations | 26 | 20 | 10 | 5 | 2 | 0 | 09/29/2017 | 319 | 143 | ||
| 26 | 20 | 10 | 5 | 2 | 0 | |||||||||
| 1 | E | Total Registrations | 20 | 15 | 8 | 4 | 2 | 0 | 09/29/2017 | |||||
| 20 | 15 | 8 | 4 | 2 | 0 | |||||||||
| NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel | 1 | E | Total Registrations | 2 | 1 | 1 | 1 | 0 | 0 | 08/24/2017 | 235 | 118 | ||
| 2 | 1 | 1 | 1 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 2 | 1 | 1 | 1 | 1 | 0 | 08/24/2017 | |||||
| 2 | 1 | 1 | 1 | 1 | 0 | |||||||||
| No | A031501-Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs | 0 | E | Total Registrations | 17 | 17 | 14 | 8 | 6 | 4 | 05/03/2018 | 219 | 115 | |
| 17 | 17 | 14 | 8 | 6 | 4 | |||||||||
| 1 | E | Total Registrations | 12 | 12 | 11 | 3 | 2 | 0 | 05/03/2018 | |||||
| 12 | 12 | 11 | 3 | 2 | 0 | |||||||||
| EA8153-Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) | 1 | E | Total Registrations | 3 | 3 | 3 | 1 | 1 | 0 | 08/08/2018 | 94 | 24 | ||
| 3 | 3 | 3 | 1 | 1 | 0 | |||||||||
| R0924-Pros, NADT+WPRT vs. NADT+P&SV RT | 1 | E | Total Registrations | 90 | 30 | 11 | 3 | 1 | 0 | 11/25/2013 | 279 | 128 | ||
| 90 | 30 | 11 | 3 | 1 | 0 | |||||||||